Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

Specimen Handling 642 pembrolizumab 565 Magnetic Resonance Spectroscopy 548 Carboplatin 426 Cisplatin 377 Cyclophosphamide 374 Biopsy 365 Paclitaxel 306 Nivolumab 303 Gemcitabine 303 Radiotherapy 274 Bevacizumab 240 Dexamethasone 209 fludarabine 207 Docetaxel 191 durvalumab 183 atezolizumab 177 Oxaliplatin 174 venetoclax 168 Fluorouracil 167 Rituximab 166 Pemetrexed 164 Capecitabine 161 Radiation 159 Doxorubicin 159 Radiosurgery 150 Etoposide 137 Ipilimumab 135 Leucovorin 133 Lenalidomide 132

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Miransertib × 90 days × Clear all

NCT04316546 2026-06-05

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡